EUVIMEDEUVIMED entdecken
Crossref

Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma

Ya'nan Ren, Teli Liu, Xingguo Hou, Yuan Yao, Pei Wang, Lei Xia iD, Song Liu, Pan Wang, Jiong Cai, Dongfeng Pan, Hua Zhu, Zhi Yang iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c01979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Ya'nan Ren und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou563000, China. Hauptthemen laut MEDLINE: Zirconium, Urinary Bladder Neoplasms, Antibodies, Monoclonal, Radioisotopes. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Guizhou Provincial Basic Research Program, National Natural Science Foundation of China, Zunyi Science and Technology Cooperation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the preclinical performance of a novel 89Zr-labeled anti-Nectin-4 monoclonal antibody, [89Zr]Zr-DFO-MW282, for PET imaging of bladder urothelial carcinoma (BUC). [89Zr]Zr-DFO-MW282 was prepared via p-isothiocyanatobenzyl-desferrioxamine (p-NCS-Bn-DFO) conjugation, achieving a radiolabeling yield exceeding 70%, radiochemical purity ≥95% post-purification, and specific activity of 36.10−63.72 GBq/μmol. [89Zr]Zr-DFO-MW282 selectively accumulated in Nectin-4-positive cells and tumors, with uptake blocked by the unlabeled MW282 antibody. Small-animal PET/CT imaging revealed sustained tumor uptake in SW780 xenografts, with a high SUVmean value of 4.46 ± 0.02 at 120 h p.i. Owing to hepatobiliary clearance, the kidney and bladder uptake was minimal, yielding excellent imaging contrast. The probe demonstrated high specificity, prolonged tumor retention, and negligible bladder background, making it a promising immuno-PET probe for precise imaging of BUC and warranting further clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZirconiumUrinary Bladder NeoplasmsAntibodies, MonoclonalRadioisotopesCell Adhesion MoleculesPositron-Emission TomographyRadiopharmaceuticalsAnimalsHumansMiceFemaleCell Line, TumorTissue DistributionPositron Emission Tomography Computed TomographyMice, Nude

Substanzen

ZirconiumZirconium-89Antibodies, MonoclonalRadioisotopesCell Adhesion MoleculesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou563000, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of N…

ORCID-Profile: Lei Xia, Zhi Yang

Förderung

  • Guizhou Provincial Basic Research Program
  • National Natural Science Foundation of China
  • Zunyi Science and Technology Cooperation Project

Zitieren

APA

Ren, Y., Liu, T., Hou, X., Yao, Y., Wang, P., Xia, L., Liu, S., Wang, P., Cai, J., Pan, D., Zhu, H., & Yang, Z. (2026). Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01979

Vancouver

Ren Y, Liu T, Hou X, Yao Y, Wang P, Xia L, et al. Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01979

BibTeX
@article{Ren2026,
  author = {Ren, Ya'nan and Liu, Teli and Hou, Xingguo and Yao, Yuan and Wang, Pei and Xia, Lei and Liu, Song and Wang, Pan and Cai, Jiong and Pan, Dongfeng and Zhu, Hua and Yang, Zhi},
  title = {Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c01979}
}
Kostenlos starten →